Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Reduction of PRC2 activity supports survival of TNBC cancer cells to cytotoxic treatments.

ABSTRACT: Basal-like breast cancer generally shows a good response to conventional cytotoxic but rapidly develops a resistant phenotype. To better understand the epigenetic changes underlying the acquisition of resistant properties, we treated the murine basal-like mammary carcinoma cell line G-2 for 48 hours with sublethal combination chemotherapy (Cyclophosphamide, Adriamycin, 5-Fluorouracil) and subsequently subjected them to RNA- and ChIP-sequencing.

INSTRUMENT(S): Illumina HiSeq 4000

ORGANISM(S): Mus musculus

SUBMITTER: Florian Wegwitz

PROVIDER: E-MTAB-9584 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Axon Guidance Receptor ROBO3 Modulates Subtype Identity and Prognosis via AXL-associated Inflammatory Network in Pancreatic Cancer

Project description:Recently, genome-wide molecular analyses have identified an altered axon guidance SLIT-ROBO signaling pathway in Pancreatic ductal adenocarcinoma (PDAC). To examine whether ROBO3 signaling is involved in the transcriptional determination of basal-like PDAC-subtype specification and functions, we performed RNA-seq analysis following ROBO3 silencing in the basal-like cell line PANC1.

2022-07-31 | E-MTAB-11476 | biostudies-arrayexpress

Reduction of PRC2 activity supports survival of TNBC cancer cells to cytotoxic treatments

Project description:Basal-like breast cancer generally shows a good response to conventional cytotoxic but rapidly develops a resistant phenotype. To better understand the epigenetic changes underlying the acquisition of resistant properties, we treated the murine basal-like mammary carcinoma cell line G-2 for 48 hours with sublethal combination chemotherapy (Cyclophosphamide, Adriamycin, 5-Fluorouracil) and subsequently subjected them to RNA- and ChIP-sequencing.

2021-11-30 | E-MTAB-9547 | biostudies-arrayexpress

ROBO3s: a novel ROBO3 shot isoform promoting breast cancer aggressiveness

Project description:We identified a novel uncharacterized short isoform of the Roundabout Guidance Receptor 3 (ROBO3) encoding for the C-terminal domain of the protein and lacking transmembrane region. We established an important role for the so-called ROBO3s isoform, mediating cancer stem cell properties by stimulating the Hippo-YAP signaling pathway, and thus driving the resistance of Basal-like breast cancer cells to cytotoxic drugs.

2022-08-31 | E-MTAB-10744 | biostudies-arrayexpress

Drug-resistant breast cancer stem cells enriched through one-dose chemo-therapy convey drug tolerance.

Project description:The murine basal-like mammary carcinoma cell line H8N8 was transplanted into syngeneic WAP-T mice and growing tumors were subjected to a single dose of combination chemotherapy (100 mg/kg body weight cyclophosphamide, 5 mg/kg BW doxorubicin and 100 mg/kg BW 5-FU, short CAF). Mice of the control group were treated with one injection vehicle solution. Three cohorts of animals were generated: control, remission, and regrowth group. Tumor cells were isolated from lesions of each group, purified by flow cytometry to remove non-tumor cells and debris, and finally subjected to whole transcriptome analysis by mRNA-sequencing.

2022-08-31 | E-MTAB-9589 | biostudies-arrayexpress

ROBO3s: a novel ROBO3 shot isoform promoting breast cancer aggressiveness

Project description:We treated the murine WAP-T cell line H8N8 with either vehicle or a sublethal dose CAF chemotherapy (Cyclophosphamide, Adriamycin, 5-Fluorouracil) for 48 hours. The surviving cells were then subjected to mRNA-sequencing.

2022-09-01 | E-MTAB-11344 | biostudies-arrayexpress

TF ChIP-seq of human acute leukemias

Project description:CEBPA/PU.1/TCF7 ChIP-seq of 6 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). Low-coverage whole genome sequencing (ChIP input) of the same samples is also included as a control to be used in peak calling.

2024-05-27 | E-MTAB-14060 | biostudies-arrayexpress

CTCF ChIP-seq of human acute leukemias

Project description:CTCF ChIP-seq of 39 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011059 (dataset).

2023-08-31 | E-MTAB-13117 | biostudies-arrayexpress

H3K27ac ChIP-seq of human acute leukemias and healthy donors

Project description:H3K27ac ChIP-seq of 79 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). In addition, 4 samples derived from CD34+ cord blood cells of healthy donors were included. Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011060 (dataset).

2023-08-31 | E-MTAB-13119 | biostudies-arrayexpress

DNA methylation (MCIP-seq) of human acute leukemias and healthy donors

Project description:To measure methylation, we employed Methyl-CpG-immunoprecipitation (MCIP) a technique which relies on a fusion protein consisting of the methyl-binding domain (MBD) of MBD2 and the Fc portion of IgG1 to detect methylated regions, exploiting the natural preference of MBD for 5-methylcytosine (5-mC). MCIP-seq was performed using the EpiMark® Methylated DNA Enrichment Kit. MCIP-seq of 77 primary samples obtained from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). Moreover, MCIP-seq of CD34+ HSPCs from 3 healthy donors is included. Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011052 (dataset).

2023-08-31 | E-MTAB-13120 | biostudies-arrayexpress

Epigenetic profiling of Juvenile Idiopathic Arthritits (JIA) patients

Project description:With H3K27ac chromatin immunoprecipitation we identified a disease-specific, inflammation-associated, (super-)enhancer signature in JIA patient synovial fluid-derived CD4+ memory/effector T cells. This signature consists of unique pathogenesis-associated epigenetic changes which extend beyond general T cell activation-induced alterations, indicating that disease-specific (super-)enhancers contribute to JIA pathogenesis. In addition, our analysis shows that there is a profound enrichment of JIA-related SNPs in (super-)enhancers in JIA patients compared to controls, illustrating the importance of these non-coding regions for disease pathogenesis. H3K27ac ChIP-sequencing of CD4+ memory/effector T cells derived from peripheral blood (PB) from healthy controls (HC) and PB or synovial fluid (SF) from JIA patients.

2015-09-15 | E-GEOD-71596 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data